S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   324.52 (+3.30%)
AAPL   128.28 (+5.79%)
MSFT   237.33 (+2.13%)
FB   265.65 (+3.12%)
GOOGL   2,071.97 (+2.48%)
TSLA   722.80 (+7.00%)
AMZN   3,145.09 (+1.69%)
NVDA   553.55 (+0.91%)
BABA   241.69 (+1.65%)
CGC   34.74 (+6.08%)
GE   13.11 (+4.55%)
MU   94.60 (+3.35%)
NIO   49.76 (+8.69%)
AMD   86.44 (+2.28%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.71 (+2.20%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   324.52 (+3.30%)
AAPL   128.28 (+5.79%)
MSFT   237.33 (+2.13%)
FB   265.65 (+3.12%)
GOOGL   2,071.97 (+2.48%)
TSLA   722.80 (+7.00%)
AMZN   3,145.09 (+1.69%)
NVDA   553.55 (+0.91%)
BABA   241.69 (+1.65%)
CGC   34.74 (+6.08%)
GE   13.11 (+4.55%)
MU   94.60 (+3.35%)
NIO   49.76 (+8.69%)
AMD   86.44 (+2.28%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.71 (+2.20%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   324.52 (+3.30%)
AAPL   128.28 (+5.79%)
MSFT   237.33 (+2.13%)
FB   265.65 (+3.12%)
GOOGL   2,071.97 (+2.48%)
TSLA   722.80 (+7.00%)
AMZN   3,145.09 (+1.69%)
NVDA   553.55 (+0.91%)
BABA   241.69 (+1.65%)
CGC   34.74 (+6.08%)
GE   13.11 (+4.55%)
MU   94.60 (+3.35%)
NIO   49.76 (+8.69%)
AMD   86.44 (+2.28%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.71 (+2.20%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   324.52 (+3.30%)
AAPL   128.28 (+5.79%)
MSFT   237.33 (+2.13%)
FB   265.65 (+3.12%)
GOOGL   2,071.97 (+2.48%)
TSLA   722.80 (+7.00%)
AMZN   3,145.09 (+1.69%)
NVDA   553.55 (+0.91%)
BABA   241.69 (+1.65%)
CGC   34.74 (+6.08%)
GE   13.11 (+4.55%)
MU   94.60 (+3.35%)
NIO   49.76 (+8.69%)
AMD   86.44 (+2.28%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.71 (+2.20%)
BAC   35.79 (+3.11%)
Log in
NYSEAMERICAN:OGEN

Oragenics Competitors

$1.02
0.00 (0.00 %)
(As of 03/1/2021 04:24 PM ET)
Add
Compare
Today's Range
$1.01
Now: $1.02
$1.07
50-Day Range
$0.42
MA: $0.44
$0.54
52-Week Range
$0.36
Now: $1.02
$2.09
Volume3.81 million shs
Average Volume32.78 million shs
Market Capitalization$78.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.64

Competitors

Oragenics (NYSEAMERICAN:OGEN) Vs. EVFM, NXTC, THTX, BLU, GHSI, and ALPN

Should you be buying OGEN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Oragenics, including Evofem Biosciences (EVFM), NextCure (NXTC), Theratechnologies (THTX), BELLUS Health (BLU), Guardion Health Sciences (GHSI), and Alpine Immune Sciences (ALPN).

Oragenics (NYSEAMERICAN:OGEN) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 44.8% of Evofem Biosciences shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 9.9% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and Evofem Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oragenics01002.00
Evofem Biosciences01602.86

Evofem Biosciences has a consensus target price of $9.7143, indicating a potential upside of 152.32%. Given Evofem Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Evofem Biosciences is more favorable than Oragenics.

Profitability

This table compares Oragenics and Evofem Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OragenicsN/A-499.13%-178.75%
Evofem BiosciencesN/A-259.47%-111.70%

Valuation & Earnings

This table compares Oragenics and Evofem Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OragenicsN/AN/A$-15,570,000.00($0.37)-2.76
Evofem BiosciencesN/AN/A$-80,030,000.00($1.31)-2.94

Evofem Biosciences is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

Evofem Biosciences beats Oragenics on 7 of the 10 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, NextCure has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 66.3% of NextCure shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 9.1% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and NextCure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oragenics01002.00
NextCure14302.25

NextCure has a consensus target price of $23.3333, indicating a potential upside of 104.50%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Oragenics.

Profitability

This table compares Oragenics and NextCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OragenicsN/A-499.13%-178.75%
NextCureN/A-10.00%-9.51%

Valuation & Earnings

This table compares Oragenics and NextCure's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OragenicsN/AN/A$-15,570,000.00($0.37)-2.76
NextCure$6.35 million49.60$-33,740,000.00($2.15)-5.32

Oragenics has higher earnings, but lower revenue than NextCure. NextCure is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

NextCure beats Oragenics on 7 of the 12 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 6.3% of Theratechnologies shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and Theratechnologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oragenics01002.00
Theratechnologies02302.60

Theratechnologies has a consensus target price of $7.1250, indicating a potential upside of 101.84%. Given Theratechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Theratechnologies is more favorable than Oragenics.

Profitability

This table compares Oragenics and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OragenicsN/A-499.13%-178.75%
Theratechnologies-37.22%-135.78%-21.36%

Valuation & Earnings

This table compares Oragenics and Theratechnologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OragenicsN/AN/A$-15,570,000.00($0.37)-2.76
Theratechnologies$63.22 million5.20$-12,500,000.00($0.14)-25.00

Theratechnologies has higher revenue and earnings than Oragenics. Theratechnologies is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

Theratechnologies beats Oragenics on 9 of the 13 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 38.4% of BELLUS Health shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 24.2% of BELLUS Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and BELLUS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oragenics01002.00
BELLUS Health02702.78

BELLUS Health has a consensus target price of $8.6167, indicating a potential upside of 114.34%. Given BELLUS Health's stronger consensus rating and higher possible upside, analysts plainly believe BELLUS Health is more favorable than Oragenics.

Profitability

This table compares Oragenics and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OragenicsN/A-499.13%-178.75%
BELLUS Health-190,199.98%-30.46%-28.77%

Valuation & Earnings

This table compares Oragenics and BELLUS Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OragenicsN/AN/A$-15,570,000.00($0.37)-2.76
BELLUS Health$30,000.0010,471.05$-25,970,000.00($0.55)-7.29

Oragenics has higher earnings, but lower revenue than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

BELLUS Health beats Oragenics on 8 of the 13 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and Guardion Health Sciences (NASDAQ:GHSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Oragenics and Guardion Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OragenicsN/A-499.13%-178.75%
Guardion Health Sciences-480.23%-75.36%-68.15%

Valuation & Earnings

This table compares Oragenics and Guardion Health Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OragenicsN/AN/A$-15,570,000.00($0.37)-2.76
Guardion Health Sciences$900,000.00318.67$-10,880,000.00N/AN/A

Guardion Health Sciences has higher revenue and earnings than Oragenics.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and Guardion Health Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oragenics01002.00
Guardion Health Sciences0000N/A

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 5.3% of Guardion Health Sciences shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 3.9% of Guardion Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Guardion Health Sciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Guardion Health Sciences beats Oragenics on 5 of the 8 factors compared between the two stocks.

Alpine Immune Sciences (NASDAQ:ALPN) and Oragenics (NYSEAMERICAN:OGEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Alpine Immune Sciences and Oragenics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alpine Immune Sciences-606.16%-80.38%-30.76%
OragenicsN/A-499.13%-178.75%

Earnings and Valuation

This table compares Alpine Immune Sciences and Oragenics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpine Immune Sciences$1.74 million177.15$-41,850,000.00($2.28)-5.68
OragenicsN/AN/A$-15,570,000.00($0.37)-2.76

Oragenics has lower revenue, but higher earnings than Alpine Immune Sciences. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alpine Immune Sciences and Oragenics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alpine Immune Sciences00603.00
Oragenics01002.00

Alpine Immune Sciences presently has a consensus target price of $19.40, indicating a potential upside of 49.81%. Given Alpine Immune Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alpine Immune Sciences is more favorable than Oragenics.

Insider and Institutional Ownership

52.9% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 12.8% of Oragenics shares are owned by institutional investors. 76.1% of Alpine Immune Sciences shares are owned by company insiders. Comparatively, 9.9% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Alpine Immune Sciences has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Summary

Alpine Immune Sciences beats Oragenics on 9 of the 13 factors compared between the two stocks.


Oragenics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Evofem Biosciences logo
EVFM
Evofem Biosciences
1.5$3.85flat$314.55 millionN/A-1.97Upcoming Earnings
Gap Down
NXTC
NextCure
1.6$11.43flat$313.00 million$6.35 million-10.12Gap Down
Theratechnologies logo
THTX
Theratechnologies
1.1$3.50flat$301.23 million$63.22 million-11.29Earnings Announcement
Analyst Downgrade
Increase in Short Interest
Gap Down
BELLUS Health logo
BLU
BELLUS Health
1.8$4.01flat$299.25 million$30,000.00-6.80Earnings Announcement
Decrease in Short Interest
GHSI
Guardion Health Sciences
0.5$2.64flat$290.07 million$900,000.000.00Upcoming Earnings
Stock Split
Increase in Short Interest
Gap Up
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$12.95flat$278.97 million$1.74 million-8.99Gap Down
SEOVF
Sernova
0.5$1.19flat$278.96 millionN/A-39.67Gap Up
Kamada logo
KMDA
Kamada
1.4$6.18flat$273.35 million$127.19 million12.88
MediciNova logo
MNOV
MediciNova
1.2$5.70flat$271.64 millionN/A0.00Decrease in Short Interest
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$5.40flat$266.92 million$2.72 million-1.36Gap Down
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.3$1.28flat$266.64 million$2.18 million-0.86Increase in Short Interest
Gap Down
Galecto logo
GLTO
Galecto
1.6$10.81flat$262.46 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Down
LRMR
Larimar Therapeutics
1.5$17.40flat$262.13 millionN/A-3.26Upcoming Earnings
News Coverage
Gap Down
Galera Therapeutics logo
GRTX
Galera Therapeutics
1.6$11.09flat$261.74 millionN/A-3.18Gap Down
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$9.00flat$261.69 million$2.71 million-15.52Increase in Short Interest
Gap Down
Tyme Technologies logo
TYME
Tyme Technologies
1.3$2.19flat$260.85 millionN/A-9.95Increase in Short Interest
Gap Down
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$11.92flat$258.72 million$11.94 million-7.27
Tricida logo
TCDA
Tricida
1.9$4.79flat$256.45 millionN/A-0.89Earnings Announcement
NuCana logo
NCNA
NuCana
1.5$5.40flat$256.05 millionN/A-5.35Decrease in Short Interest
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.4$6.97flat$254.76 million$2.42 million-6.11Decrease in Short Interest
Gap Down
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$6.16flat$253.55 millionN/A-4.93Increase in Short Interest
Gap Down
Cerecor logo
CERC
Cerecor
2.1$3.70flat$252.45 million$6.75 million-12.33Gap Down
Agile Therapeutics logo
AGRX
Agile Therapeutics
1.6$3.01flat$250.94 millionN/A-6.02Gap Down
Lannett logo
LCI
Lannett
2.0$6.05flat$250.90 million$545.74 million-8.40
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.4$1.74flat$249.54 millionN/A0.00Decrease in Short Interest
Gap Down
Jaguar Health logo
JAGX
Jaguar Health
0.9$2.12flat$247.42 million$5.78 million-0.31Decrease in Short Interest
Gap Down
Theratechnologies logo
THERF
Theratechnologies
0.5$3.21flat$247.02 million$45.18 million0.00High Trading Volume
CTI BioPharma logo
CTIC
CTI BioPharma
1.3$3.28flat$245.28 million$3.35 million-4.82Decrease in Short Interest
Matinas BioPharma logo
MTNB
Matinas BioPharma
1.3$1.30flat$241.33 million$90,000.00-10.00Upcoming Earnings
Gap Down
Enlivex Therapeutics logo
ENLV
Enlivex Therapeutics
1.4$14.85flat$240.97 millionN/A-20.07Decrease in Short Interest
Gap Down
Abeona Therapeutics logo
ABEO
Abeona Therapeutics
1.5$2.33flat$238.44 million$3 million-2.24Unusual Options Activity
Gap Down
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
1.2$8.49flat$237.96 million$28.80 million-5.48Gap Down
OSMT
Osmotica Pharmaceuticals
1.1$3.79flat$237.82 million$240.03 million-4.12Gap Down
Aptinyx logo
APTX
Aptinyx
1.4$3.72flat$231.52 million$3.67 million-2.95
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.63flat$230.29 millionN/A-2.90
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$4.77flat$229.15 millionN/A-3.88Earnings Announcement
Chiasma logo
CHMA
Chiasma
1.7$3.95flat$224.86 millionN/A-2.72Upcoming Earnings
Gap Down
LTUS
Lotus Pharmaceuticals
0.0$0.06flat$223.49 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Up
Genprex logo
GNPX
Genprex
1.0$5.37flat$223.31 millionN/A-8.80Decrease in Short Interest
IMV logo
IMV
IMV
0.8$3.52flat$222.74 million$430,000.00-7.65Gap Down
Metacrine logo
MTCR
Metacrine
1.7$9.39flat$220.63 millionN/A0.00Upcoming Earnings
NeuBase Therapeutics logo
NBSE
NeuBase Therapeutics
1.3$9.91flat$219.75 millionN/A-11.01Gap Down
IMRA
IMARA
1.4$13.96flat$219.15 millionN/A0.00Upcoming Earnings
News Coverage
Gap Down
Neptune Wellness Solutions logo
NEPT
Neptune Wellness Solutions
1.3$1.59flat$218.03 million$22.05 million-3.18Gap Down
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$3.32flat$217.90 million$1.71 million-7.22Gap Down
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
1.2$1.74flat$214.44 million$40,000.00-0.43Increase in Short Interest
Gap Down
Milestone Pharmaceuticals logo
MIST
Milestone Pharmaceuticals
1.4$7.52flat$214.43 millionN/A-3.20Upcoming Earnings
News Coverage
Gap Down
Strongbridge Biopharma logo
SBBP
Strongbridge Biopharma
1.5$3.17flat$211.15 million$21.71 million-3.48Upcoming Earnings
Gap Down
Calithera Biosciences logo
CALA
Calithera Biosciences
1.7$2.88flat$206.03 million$22.25 million-2.09
Concert Pharmaceuticals logo
CNCE
Concert Pharmaceuticals
1.7$6.92flat$205.04 million$1.08 million-2.69Earnings Announcement
Decrease in Short Interest
Gap Down
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.